Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LACbes Left Atrial Appendage Occlusion: DAPT vs Rivaroxaban
ChiCTR2100046712Phase 4Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Atrial fibrillation (AFib) comparing Dual antiplatelet therapy (aspirin + ticagrelor) with Rivaroxaban (2 arms). Primary endpoints: Clinical thromboembolic events at 12 months, Device-related thrombosis at 12 months and 2 more. Started Feb 2023; status: recruiting.
02
Drugs
aspirinticagrelorrivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2100046712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046712.